secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptimmune Therapeutics PLC (—)
CIK:        0001621227
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001558370-24-015525
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptimmune reports Q3 net loss $17.6M; plans 33% headcount cut, $300M in savings through 2028
--------------------------------------------------------------------------------

- Q3 net loss $17.6M (EPS -$0.01); revenue $40.9M up from $7.3M due to Genentech/Astellas termination revenue.
- Plans 33% headcount reduction in Q1 2025; expects $300M cost savings over 4 years, targeting breakeven in 2027.
- Tecelra launch: 9 ATCs active, first patient apheresed; commercial revenues expected in Q4.
- Lete-cel pivotal trial: 42% ORR (6 CR, 21 PR) in synovial sarcoma/MRCLS; BLA planned by end-2025.
- Ended Q3 with total liquidity $186.1M; ceasing SURPASS-3 trial for ovarian cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621227/000155837024015525/0001558370-24-015525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621227/000155837024015525/adap-20241113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer